| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/200 - 1/1000 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 1/200 - 1/400 | Human,Mouse,Rat |
| Elisa | 1/10000 | Human,Mouse,Rat |
| Aliases | GBP; GAL1 |
| Entrez GeneID | 3956 |
| clone | 1H11C5 |
| WB Predicted band size | 14.7kDa |
| Host/Isotype | Mouse IgG1 |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Purified recombinant fragment of human LGALS1 (AA: 1-135) expressed in E. Coli. |
| Formulation | Purified antibody in PBS with 0.05% sodium azide |
+ +
以下是3篇与LGALS1(Galectin-1)抗体相关研究的模拟文献示例(注：内容为模拟概括，实际引用请核对原文)：
1. **文献名称**: *Galectin-1 as a potential therapeutic target in glioblastoma*
**作者**: Le Mercier M, et al.
**摘要**: 研究利用抗LGALS1抗体阻断胶质母细胞瘤细胞中Galectin-1的功能，发现其抑制肿瘤血管生成并增强化疗敏感性，提示靶向Galectin-1的临床潜力。
2. **文献名称**: *Antibody-mediated neutralization of Galectin-1 inhibits axonal regeneration in the peripheral nervous system*
**作者**: Höke A, et al.
**摘要**: 通过抗LGALS1抗体阻断Galectin-1活性，发现其显著抑制周围神经损伤后的轴突再生，揭示了Galectin-1在神经修复中的关键作用。
3. **文献名称**: *Targeting Galectin-1 in tumor-associated macrophages enhances antitumor immunity*
**作者**: Rubinstein N, et al.
**摘要**: 研究使用抗LGALS1抗体调节肿瘤微环境中巨噬细胞的表型，证明阻断Galectin-1可逆转免疫抑制并促进T细胞抗肿瘤反应。
4. **文献名称**: *Galectin-1 expression correlates with melanoma progression and immune evasion*
**作者**: Viguier M, et al.
**摘要**: 通过免疫组化(抗LGALS1抗体)分析黑色素瘤样本，发现Galectin-1高表达与患者预后不良及PD-1耐药相关，提示其作为免疫治疗联合靶点。
建议通过PubMed或Web of Science以“LGALS1 antibody”或“Galectin-1 inhibitor”为关键词检索最新文献。
**Background of LGALS1 Antibody**
LGALS1 (Galectin-1) is a protein encoded by the *LGALS1* gene, belonging to the galectin family of β-galactoside-binding lectins. It plays a multifaceted role in cellular processes, including cell adhesion, proliferation, apoptosis, and immune regulation. Galectin-1 is expressed in various tissues and cell types, such as immune cells, endothelial cells, and neurons, and is involved in modulating inflammatory responses, angiogenesis, and tumor progression. Its dual role in cancer—acting as both a tumor suppressor and promoter—depends on context-specific factors like microenvironmental cues and post-translational modifications.
LGALS1 antibodies are valuable tools for studying galectin-1's expression patterns, localization, and functional roles in physiological and pathological states. They are widely used in techniques like Western blotting, immunohistochemistry (IHC), and flow cytometry to detect galectin-1 in research areas spanning oncology, immunology, and neurobiology. For instance, LGALS1 antibodies help elucidate its immunosuppressive effects in tumor microenvironments or its neuroprotective roles in neurodegenerative diseases. Dysregulation of galectin-1 is linked to cancers, chronic inflammation, and autoimmune disorders, making it a potential therapeutic target. Antibodies against LGALS1 also serve as investigative probes for developing galectin-1-targeted therapies, including inhibitors to block its immunosuppressive or pro-angiogenic activities.
×
